13 completed, 6 terminated, 6 unknown, 4 recruiting. 15 Phase 2, 8 Phase 1, 3 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow Human Epidermal Growth Factor 2 Negative Carcinoma of Breast: new trials by email Literature Review of Human Epidermal Growth Factor 2 Negative Carcinoma of Breast trials Research Report on Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) Capecitabine, Elacestrant - Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | Kristina A. Fanucci | 297 | 2026-01-16 | 2026-08-26 |
| Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery Trastuzumab emtansine, Pertuzumab Injection, Docetaxel - Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer | Phase 2 | Recruiting | University of Chicago | 74 | 2025-03-18 | 2026-02-17 |
| Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer SHR-A1921, Adebrelimab - Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer | Phase 2 | Unknown | Fudan University | 32 | 2024-12-01 | 2024-12-20 |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NKT3964, Paclitaxel, Doxorubicin - Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | NiKang Therapeutics, Inc. | 238 | 2024-09-19 | 2026-10-16 |
| Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients. Palbociclib - Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Unknown | Helwan University | 100 | 2024-07-01 | 2024-03-29 | |
| A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NKT3447 - Solid Tumor, Solid Tumor, Adult | Phase 1 | Terminated | NiKang Therapeutics, Inc. | 23 | 2024-02-23 | 2025-09-25 |
| Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer INX-315, Fulvestrant, Abemaciclib - Breast Cancer, Breast Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Incyclix Bio | 150 | 2023-03-28 | 2026-04-01 |
| Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Completed | Novartis | 121 | 2020-04-06 | 2024-06-18 | |
| PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) Palbociclib, Endocrine therapy - Breast Cancer, Advanced Breast Cancer | Phase 2 | Completed | MedSIR | 198 | 2019-04-05 | 2023-09-07 |
| WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor Palbociclib, Bosutinib, Fulvestrant - Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 1 | Completed | Georgetown University | 19 | 2019-04-01 | 2025-02-06 |
| A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer Oral NVB Metronomic, Oral NVB Weekly - Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 172 | 2019-02-20 | 2019-02-26 |
| Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer Palbociclib, Tamoxifen - Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 2 | Completed | Oana Danciu, MD | 49 | 2017-02-01 | 2026-01-20 |
| Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant Palbociclib, Letrozole, Anastrozole - Breast Cancer, Hormone Receptor Positive Tumor | Phase 2 | Completed | iOMEDICO AG | 388 | 2016-09-06 | 2023-03-13 |
| Palbociclib With Everolimus + Exemestane In BC Palbociclib, Everolimus, Exemestane - Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 41 | 2016-08-24 | 2022-08-29 |
| ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism ME-344, Bevacizumab, Normal saline - Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Early Phase 1 | Completed | Centro Nacional de Investigaciones Oncologicas CARLOS III | 40 | 2016-07-01 | 2019-07-23 |
| A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older Breast Cancer Treatment Decision Aid for women 70+, Usual Care - Breast Cancer, Estrogen Receptor Positive Breast Cancer | Not applicable | Terminated | Beth Israel Deaconess Medical Center | 65 | 2016-07-01 | 2024-01-05 |
| Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer Rebastinib, Paclitaxel, Eribulin Mesylate - Breast Cancer, Breast Adenocarcinoma | Phase 1 | Terminated | Montefiore Medical Center | 28 | 2016-07-01 | 2022-04-04 |
| A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer Eribulin, Adriamycin, Cyclophosphamide - Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 22 | 2016-02-26 | 2026-07-06 |
| Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer Everolimus, Exemestane, Fulvestrant - Metastatic Breast Cancer, Breast Cancer | Phase 3 | Unknown | Consorzio Oncotech | 745 | 2015-12-01 | 2016-06-15 |
| Patterns of Prescribing and Monitoring of Palbociclib Palbociclib - Metastatic Breast Cancer, Advanced Breast Cancer | Completed | Rush University Medical Center | 67 | 2015-02-03 | 2023-03-31 |
Showing 20 of 30. Sign in to see all of them.
Breast Neoplasms (21) · Neoplasm Metastasis (8) · Ovarian Neoplasms (4) · Triple Negative Breast Neoplasms (3) · Breast Neoplasms, Male (2) · Endometrial Neoplasms (2) · Small Cell Lung Carcinoma (2) · Stomach Neoplasms (2) · Uterine Diseases (2) · Inflammatory Breast Neoplasms (1) · Neoplasms (1) · Neoplastic Cells, Circulating (1)
Breast Diseases (24) · Neoplasms (24) · Neoplasms by Site (24) · Skin Diseases (24) · Skin and Connective Tissue Diseases (24) · Neoplastic Processes (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Adnexal Diseases (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Genital Diseases, Female (4)
palbociclib (7) · Fulvestrant (5) · Doxorubicin (4) · Paclitaxel (4) · Bevacizumab (3) · Letrozole (3) · eribulin (3) · exemestane (3) · Anastrozole (2) · Capecitabine (2) · Cyclophosphamide (2) · Everolimus (2) · Tamoxifen (2) · 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine (1) · Ado-Trastuzumab Emtansine (1)
Consorzio Oncotech (2) · Dana-Farber Cancer Institute (2) · NiKang Therapeutics, Inc. (2) · University of Arizona (2) · Beth Israel Deaconess Medical Center (1) · Borstkanker Onderzoek Groep (1) · Centro Nacional de Investigaciones Oncologicas CARLOS III (1) · Chinese Academy of Medical Sciences (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fudan University (1) · Georgetown University (1) · Guangdong Academy of Medical Sciences (1) · Helwan University (1) · Incyclix Bio (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1)
United States (15) · Italy (5) · China (3) · France (3) · Germany (3) · Spain (3) · United Kingdom (3) · Belgium (2) · Netherlands (2) · Australia (1) · Canada (1) · Greece (1) · Hungary (1) · Iceland (1) · Israel (1)
Alison Stopeck (1) · Brigitte Rack, MD (1) · Christos Sotiriou, MD (1) · Claudine Isaacs, MD (1) · Dino Amadori, MD (1) · Filipa Lynce, MD (1) · Grazia Arpino, MD (1) · Hongxia Wang (1) · Jean-Yves Pierga, MD (1) · Jesus D Anampa Mesias, M.D (1) · Kathryn Schultz (1) · Kristina Fanucci, MD (1)
PMID 15215160, PMID 15313917, PMID 15681523, PMID 15755984, PMID 16172161, PMID 16172168, PMID 17016557, PMID 17647245, PMID 18443902, PMID 18854571, PMID 19097774, PMID 19289619, PMID 19349550, PMID 19720913, PMID 20299316, PMID 20450446, PMID 20498403, PMID 20679609, PMID 21376385, PMID 21383283, PMID 21990397, PMID 23168366, PMID 27289552, PMID 32200486, PMID 40294349, PMID 40957562, PMID 41024110, PMID 8708708, PMID 9034784
2009 (2), P30CA023074 (2), 2014 (1), 2015 (1), 2017 (1)